- Home
- CGNT vs ZURA Comparison
CGNT vs ZURA Comparison
Compare CGNT & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGNT | ZURA |
|---|---|---|
| Founded | 2020 | 2022 |
| Country | Israel | United States |
| Employees | N/A | 30 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 588.7M | 521.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | CGNT | ZURA |
|---|---|---|
| Price | $8.74 | $6.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $13.50 | $11.78 |
| AVG Volume (30 Days) | 391.3K | ★ 514.5K |
| Earning Date | 03-25-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.85 | N/A |
| Revenue Next Year | $13.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.29 | $0.99 |
| 52 Week High | $11.66 | $7.25 |
Technical Indicators
Market Signals| Indicator | CGNT | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 60.54 | 49.48 |
| Support Level | $8.01 | $5.49 |
| Resistance Level | $8.95 | $6.99 |
| Average True Range (ATR) | 0.46 | 0.49 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 66.35 | 60.14 |
Price Performance
Historical ComparisonAbout CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.